Sensitech to Strengthen Life Sciences Cold Chain Solutions with Acquisition of Berlinger & Co. Monitoring Solutions
BEVERLY, Mass., June 19, 2024 /PRNewswire/ -- Carrier Global Corporation, on behalf of its Sensitech business, a world leader in...
Vaccine
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to Women Undergoing Breast Cancer Treatment
Breast cancer patients in Switzerland will receive access to a personalized digital therapeutic designed to optimize their experience and health...
Rapid Dose Provides Update on Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - June 19, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that...
New England Biolabs® and Inorevia to partner on novel solutions for the preparation of challenging samples for next generation sequencing
IPSWICH, Mass. and PARIS, June 18, 2024 /PRNewswire/ -- New England Biolabs (NEB ®) and Inorevia announce a collaboration to...
Zynext Ventures, the VC arm of Zydus Lifesciences, Announces Investment in Promaxo: Pioneering Point-of-Care Medical Imaging and Interventions with Next Generation MRI Systems
PENNINGTON, N.J., June 18, 2024 /PRNewswire/ -- Zynext Ventures USA LLC (Zynext Ventures), the Venture Capital (VC) arm of Zydus...
NFID Launches New Spanish Website for Disease Prevention and Treatment
New Spanish Website Aims to Educate and Empower Patients, Caregivers, and Healthcare Professionals to Make Informed Health Decisions BETHESDA, Md.,...
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Elicio Therapeutics Reports Inducement Grants
BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company...
Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License
ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company...
SpyBiotech Appoints Keith Dewedoff as new Chief Financial Officer
OXFORD, England and CAMBRIDGE, Mass., June 18, 2024 /PRNewswire/ -- SpyBiotech, a biotechnology company with a novel vaccine platform technology...
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s...
Defence’s Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to...
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains...
Velocity Clinical Research partners with Luminis Health, moves into oncology in the U.S.
Velocity President and Chief Executive, Dr Paul Evans Velocity President and Chief Executive, Dr Paul Evans DURHAM, N.C., June 12,...
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy
Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors.TAIPEI, Taiwan, June 12, 2024 (GLOBE NEWSWIRE)...
Ruvidar(TM) Enhances Efficacy of Cancer Drug
TORONTO, ON / ACCESSWIRE / June 10, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines...
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or...
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending...